HC Wainwright Reaffirms “Buy” Rating for Sana Biotechnology (NASDAQ:SANA)

HC Wainwright restated their buy rating on shares of Sana Biotechnology (NASDAQ:SANA) in a report issued on Monday morning,Benzinga reports. They currently have a $8.00 price target on the stock.

Other equities analysts also recently issued research reports about the company. JMP Securities downgraded Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 5th. Citigroup raised their target price on Sana Biotechnology from $8.00 to $15.00 and gave the company a “buy” rating in a report on Friday, August 9th.

Sana Biotechnology Stock Performance

Shares of NASDAQ:SANA opened at $2.59 on Monday. Sana Biotechnology has a 52 week low of $2.55 and a 52 week high of $12.00. The firm has a market cap of $578.27 million, a PE ratio of -1.85 and a beta of 1.44. The firm’s fifty day moving average is $3.97 and its 200-day moving average is $5.64.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings results on Friday, November 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.01. Sell-side analysts forecast that Sana Biotechnology will post -1.14 EPS for the current year.

Insider Transactions at Sana Biotechnology

In related news, Director Richard Mulligan sold 150,000 shares of the firm’s stock in a transaction dated Tuesday, September 24th. The shares were sold at an average price of $4.08, for a total transaction of $612,000.00. Following the completion of the sale, the director now owns 2,848,121 shares in the company, valued at approximately $11,620,333.68. This trade represents a 5.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 31.10% of the company’s stock.

Hedge Funds Weigh In On Sana Biotechnology

Several institutional investors and hedge funds have recently bought and sold shares of SANA. ProShare Advisors LLC lifted its position in shares of Sana Biotechnology by 14.8% during the 1st quarter. ProShare Advisors LLC now owns 32,690 shares of the company’s stock valued at $327,000 after buying an additional 4,210 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Sana Biotechnology by 20.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,858 shares of the company’s stock worth $163,000 after purchasing an additional 5,090 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Sana Biotechnology by 17.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 35,196 shares of the company’s stock valued at $146,000 after buying an additional 5,338 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Sana Biotechnology by 2.8% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 253,899 shares of the company’s stock worth $1,056,000 after buying an additional 6,823 shares during the period. Finally, Arizona State Retirement System grew its stake in Sana Biotechnology by 36.7% in the 2nd quarter. Arizona State Retirement System now owns 37,028 shares of the company’s stock valued at $202,000 after buying an additional 9,940 shares in the last quarter. 88.23% of the stock is owned by institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.